Vega LRM, Mendiola AE

Language: Spanish
References: 13
Page: 457-462
PDF size: 167.72 Kb.

ABSTRACT

Introduction: The efficient and opportune treatment of anxiety associated with depression is important because we need to avoid the associated repercussions to its inadequate processing at the level of health, economic, self-esteem and labor. Objective: To evaluate the efficacy and security of the combination of paroxetin and alprazolam in patients with generalized anxiety associated with depression. Material and methods: A longitudinal, prospective, open clinical study was carried out and was evaluated in 4 phases in an interim of 12 weeks after the initial visit. The patients received the combination of paroxetin-alprazolam in fixed doses once a day and included 56 patients diagnosed with generalized anxiety and depression were included according to the DSM-IV. Results: The combination fixed paroxetin-alprazolam was a good option for the management of the anxiety symptoms, due to a significant reduction in the severity in the different symptoms as was observed in the scales utilized during the 4 visits. Conclusion: The combination paroxetin-alprazolam offers important benefits as increases the efficacy due to its synergistic interaction, reduction of dosages of the drugs by consequence of the adverse events, prevention of tolerance, besides combining the quickness of a benzodiazepine with the efficacy of an ISRS.

REFERENCES

1. Baldwin DS, Anderson IM, Nutt DJ. Evidence guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for psychopharmacology. J Psychopharmacol 2005; 18: 567-96.

2. Boussard M, Gaspar E, Labraga P, Dóttone A. Pautas terapéuticas de los trastornos de ansiedad. Rev Psiquiatr Urug 2002; 66: 130-52.

3. Reus VI. Trastornos mentales. Sección 5: Trastornos psiquiátricos. En: Harrison. Principios de Medicina interna. 16a Ed. Mc. Graw Hill Interamericana Editores; 2003, p. 2811.

4. Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM, Poulton R. Depression and Generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 2007; 64: 651-60.

5. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007).

6. Baldessarini RJ. Fármacos y tratamiento para trastornos psiquiátricos. Depresión y trastornos de ansiedad. En: Goodman, Gilman: Las Bases Farmacológicas de la Terapéutica. McGraw Hill Interamericana Editores; 2003, p. 455-91.

7. Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety 1999; 9: 107-16

8. Calvo G, García-Gea C, Luque A, Morte A, Dal-Ré R, Barbanoj M. Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy Volunteers. J Clin Psycopharmacol 2004; 24: 268-76.

9. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355-64.

10. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in Treatment Outcome in Outpatients with Anxious Versus Nonanxious Depression: A STAR*D Report. Am J Psychiatry 2008; 165: 342-51.

11. Brawman-Mintzer O. Pharmacologic treatment of generalized anxiety disorders. Psychiatr Clin North Am 2001; 24: 111-37.

12. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci 1996; 58: 23-28.

13. Tallarida RJ, Stone DJ Jr, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sci 1997; 61: 417-25.